Clinical Trial

Allogeneic UCB-derived CAR-T for SLE

Name: Allogeneic UCB-derived CAR-T for SLE — clinical trial record (NCT07274059)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this clinical trial is to learn if allogeneic, umbilical cord blood-derived chimeric antigen receptor T-cell (UCAR-T) targeting CD19 and BCMA works to treat refractory SLE in adults. It will also learn about the safety and efficacy of the UCAR-T cell product.

Trial Details

NCT Number	NCT07274059
Lead Sponsor	Chengdu Ucello Biotechnology Co., Ltd. Collaborators: The General Hospital of Western Theater Command, Yancheng Third People's Hospital
Conditions	SLE - Systemic Lupus Erythematosus
Enrollment	48 participants
Start Date	2025-03-26
Primary Completion	2035-12-31 (estimated)
Study Completion	2037-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-12-10